- Home
- CAAP vs KNSA Comparison
CAAP vs KNSA Comparison
Compare CAAP & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAAP | KNSA |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | Luxembourg | United Kingdom |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.9B |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CAAP | KNSA |
|---|---|---|
| Price | $25.11 | $62.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $26.73 | ★ $60.86 |
| AVG Volume (30 Days) | 185.9K | ★ 905.3K |
| Earning Date | 05-21-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $5.80 | $37.48 |
| Revenue Next Year | $2.36 | $17.87 |
| P/E Ratio | ★ $26.35 | $233.52 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $17.36 | $26.51 |
| 52 Week High | $30.50 | $67.53 |
Technical Indicators
Market Signals| Indicator | CAAP | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 55.14 |
| Support Level | $24.78 | $60.07 |
| Resistance Level | $26.76 | $67.53 |
| Average True Range (ATR) | 0.66 | 2.60 |
| MACD | 0.04 | -0.45 |
| Stochastic Oscillator | 61.62 | 33.82 |
Price Performance
Historical ComparisonAbout CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.